Given the risk of an increase in the circulation of dengue serotype DENV-3 in the southern hemisphere of the Americas Region during the peak dengue season, the Pan American Health Organization / World Health Organization (PAHO/WHO) urges Member States to prepare for a possible increase in cases and ensure early diagnosis and timely care dengue and other arbovirus cases, in order to prevent severe cases and deaths associated with these diseases.
The occurrence and magnitude of dengue outbreaks are usually associated with the introduction or increase in circulation of a serotype other than the one that previously predominated in an affected region.
For details, see PAHO publication.
Prevention: Optimal mosquito protection 24/7, also in cities (also against other mosquito-borne diseases such as Zika, chikungunya, oropouche, malaria).
In case of fever, ensure adequate hydration and apply paracetamol products. If you have a fever, avoid tak-ing medications containing acetylsalicylic acid (e.g., Aspirin®), as this can increase the risk of bleeding during a dengue infection. However, do not stop tak-ing medications containing acetylsalicylic acid if it is already part of your regular treatment for an underly-ing condition.
Note on vaccination against dengue fever with Qdenga®:
- The Swiss Expert Committee for Travel Medicine (ECTM) recommends a vaccination with Qdenga® only for travelers from 6 years old who have evi-dence of previous dengue infection and who will be exposed in a region with significant dengue transmission.
- Studies have shown reduced seroprotection against dengue serotype DENV-3 in patient vac-cinated with Qdenga®, especially in dengue-naïve individuals.
For details, see ECTM Statement.